NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · MID CAP
NRC Health NRC
17 fiscal years on record · USD · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in NRC HEALTH's annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.
Growth
USD 137.4M
Revenue, FY2025 · full 17-year series below
Revenue $M
Net income $M
FY2025 · Revenue 137.4 · Net income 11.6
Compound annual growth
−3.2%
+0.6%
+3.0%
+5.3%
−28.5%
−20.8%
+240.2%
+103.0%
−14.8%
+19.9%
−13.9%
+24.2%
+10.2%
+12.7%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +0.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
8 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 16.4% · Net 8.4%
ROE
FY2018 · ROE 55.1%
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
The share count changed between 2012 and 2017, but the exact year can't be marked here — the underlying count wasn't on file for every year in that stretch.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Operating income $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Free cash flow $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EPS, diluted $ | 50.00 | 1.04 | 1.25 | 1.27 | · | 1.45 | 1.26 | · | · | · | · | · | · | 2.17 | 1.69 | 1.26 | 1.26 |
| Dividend / sh $ | 0.52 | 0.48 | 1.48 | 0.84 | 0.48 | 0.21 | 0.78 | · | · | · | · | · | · | 2.54 | 0.88 | 0.76 | 0.64 |
| Payout % | · | · | · | · | · | · | · | 56 | 74 | 139 | 57 | · | 14 | 115 | 51 | 44 | 50 |
| ROE % | · | · | · | · | · | · | · | 55.1 | 26.5 | 26.1 | 21.7 | 22.8 | 24.1 | 26.8 | 22.2 | 24.9 | 19.2 |
| Shares out B | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | · | · | · | · | 0.01 | 0.01 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 1 failures in 59 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 19 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityServices-Commercial Physical & Biological Research
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009